Nirsevimab is efficacious for preventing hospitalization for respiratory syncytial virus (RSV)-associated lower respiratory tract infection among infants, according to a study published in the Dec. 28 issue of the New England Journal of Medicine.
Nirsevimab is efficacious for preventing hospitalization for respiratory syncytial virus (RSV)-associated lower respiratory tract infection among infants, according to a study published in the Dec. 28 issue of the New England Journal of Medicine.
Leave A Comment